A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting

New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanyal, Debmalya, Gupta, Soumava, Das, Pratik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830305/
https://www.ncbi.nlm.nih.gov/pubmed/24251159
http://dx.doi.org/10.4103/2230-8210.119572
_version_ 1782291472816537600
author Sanyal, Debmalya
Gupta, Soumava
Das, Pratik
author_facet Sanyal, Debmalya
Gupta, Soumava
Das, Pratik
author_sort Sanyal, Debmalya
collection PubMed
description New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is effective for glycemic control in NODAT, even on glucocorticoids and standard dose of tacrolimus. There was no alteration of tacrolimus drug levels or estimated glomerular filtration rate (eGFR) and minimal side effects, including weight gain and hypoglycemia. Well-designed, powered randomized controlled of antiglycemic agents in NODAT are needed.
format Online
Article
Text
id pubmed-3830305
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38303052013-11-18 A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting Sanyal, Debmalya Gupta, Soumava Das, Pratik Indian J Endocrinol Metab Brief Communication New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is effective for glycemic control in NODAT, even on glucocorticoids and standard dose of tacrolimus. There was no alteration of tacrolimus drug levels or estimated glomerular filtration rate (eGFR) and minimal side effects, including weight gain and hypoglycemia. Well-designed, powered randomized controlled of antiglycemic agents in NODAT are needed. Medknow Publications & Media Pvt Ltd 2013-10 /pmc/articles/PMC3830305/ /pubmed/24251159 http://dx.doi.org/10.4103/2230-8210.119572 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Sanyal, Debmalya
Gupta, Soumava
Das, Pratik
A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
title A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
title_full A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
title_fullStr A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
title_full_unstemmed A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
title_short A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
title_sort retrospective study evaluating efficacy and safety of linagliptin in treatment of nodat (in renal transplant recipients) in a real world setting
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830305/
https://www.ncbi.nlm.nih.gov/pubmed/24251159
http://dx.doi.org/10.4103/2230-8210.119572
work_keys_str_mv AT sanyaldebmalya aretrospectivestudyevaluatingefficacyandsafetyoflinagliptinintreatmentofnodatinrenaltransplantrecipientsinarealworldsetting
AT guptasoumava aretrospectivestudyevaluatingefficacyandsafetyoflinagliptinintreatmentofnodatinrenaltransplantrecipientsinarealworldsetting
AT daspratik aretrospectivestudyevaluatingefficacyandsafetyoflinagliptinintreatmentofnodatinrenaltransplantrecipientsinarealworldsetting
AT sanyaldebmalya retrospectivestudyevaluatingefficacyandsafetyoflinagliptinintreatmentofnodatinrenaltransplantrecipientsinarealworldsetting
AT guptasoumava retrospectivestudyevaluatingefficacyandsafetyoflinagliptinintreatmentofnodatinrenaltransplantrecipientsinarealworldsetting
AT daspratik retrospectivestudyevaluatingefficacyandsafetyoflinagliptinintreatmentofnodatinrenaltransplantrecipientsinarealworldsetting

Ejemplares similares